Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program

Tognim, Maria Cristina Bronharo; Andrade, Sheila Siqueira; Silbert, Suzane; Gales, Ana Cristina; Jones, Ronald N.; Sader, Hélio S.

doi:10.1016/j.ijid.2003.11.009

Cited by 61 publications

(49 citation statements)

References 24 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acinetobacter has considerable capacity to spread and develop new antibiotic resistance mechanisms (5) . Consequently, numerous HAI outbreaks caused by multidrug-resistant (MDR) representatives of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex have been reported in several countries, including Brazil (2) (5) (6) .…”

Section: Introductionmentioning

confidence: 99%

The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting

Kobs¹,

Ferreira

Bobrowicz

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Members of the Acinetobacter genus are key pathogens that cause healthcare-associated infections, and they tend to spread and develop new antibiotic resistance mechanisms. Oxacillinases are primarily responsible for resistance to carbapenem antibiotics. Higher rates of carbapenem hydrolysis might be ascribed to insertion sequences, such as the ISAba1 sequence, near bla OXA genes. The present study examined the occurrence of the genetic elements bla OXA and ISAba1 and their relationship with susceptibility to carbapenems in clinical isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Methods: Isolates identifi ed over 6 consecutive years in a general hospital in Joinville, Southern Brazil, were evaluated. The investigation of 5 families of genes encoding oxacillinases and the ISAba1 sequence location relative to bla OXA genes was conducted using polymerase chain reaction. Results: All isolates presented the bla OXA-51-like gene (n = 78), and 91% tested positive for the bla OXA-23-like gene (n = 71). The presence of ISAba1 was exclusively detected in isolates carrying the bla OXA-23-like gene. All isolates in which ISAba1 was found upstream of the bla OXA-23-like gene (n = 69) showed resistance to carbapenems, whereas the only isolate in which ISAba1 was not located near the bla OXA-23-like gene was susceptible to carbapenems. The ISAba1 sequence position of another bla OXA-23-like -positive isolate was inconclusive. The isolates exclusively carrying the bla OXA-51-like gene (n = 7) showed susceptibility to carbapenems. Conclusions: The presence of the ISAba1 sequence upstream of the bla OXA-23-like gene was strongly associated with carbapenem resistance in isolates of the A. calcoaceticus-A. baumannii complex in the hospital center studied.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting

Kobs¹,

Ferreira

Bobrowicz

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Las UCI son un lugar frecuente de adquisición de ABM; esto tiene relación con el tipo de pacientes internados, la exposición a procedimientos invasores y a esquemas antimicrobianos de amplio espectro, sumado a la posible transmisión horizontal que puede ocurrir ocasionando brotes [16][17][18] .…”

Section: Discussionunclassified

“…Infecciones Asociadas a la Atención de Salud dos 18 . La frecuencia de bacteriemia primaria observada en nuestro estudio fue similar a la reportada en otra serie 19 .…”

Section: Artículo Originalunclassified

Factores de riesgo para la adquisición y características microbiológicas de las bacteriemias por Acinetobacter baumannii multi-resistente en pediatría: Estudio de casos y controles

Ruvinsky

Fiorilli

Pérez

et al. 2015

Rev. chil. infectol.

View full text Add to dashboard Cite

“…It is invariably multiresistant and one major concern is the increasing incidence of carbapenem-resistant isolates, since these antibiotics are frequently the therapeutic choice for these infections [2]. Carbapenem resistance in South America has already reached levels that significantly influence therapeutic choices [3,4] and this looks set to be a problem in several other regions [5,6]. Acinetobacter spp.…”

mentioning

confidence: 99%

“…has been found at the fourth rank in hospitalized patients with pneumonia in Latin America [6] and at the second one in patients with nosocomial pneumonia in Argentina [7], with carbapenem resistance increasing dramatically [4], especially in Argentina [4,7] and in Colombia [4,8]. This kind of resistance has also been reported at modest rates in Chile [4] and Brazil [4,9], albeit it seems to remain stable in some regions of this late country [10]. As a result, old antibiotics, such as colistin and ampicillinsulbactam, have emerged as the obligate alternative for treating serious infections associated with A. baumannii [11].…”

mentioning

confidence: 99%

Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model

Bantar¹,

Canigia²,

Berger³

et al. 2009

Braz J Infect Dis

View full text Add to dashboard Cite

Amoxicillin-sulbactam (AMX-SUL) is an aminopenicillin/ß-lactamase inhibitor combination currently available in 29 countries and may be a suitable option for treating infections caused by Acinetobacter spp. Thus, we sought to search the optimal dosing strategy for this formulation through an ex vivo pharmacodynamic human model against Acinetobacter baumanniii. Four volunteers were randomized to receive alternatively a single dose AMX-SUL infused both either over 30 min or 3h at the following ratios (g/g): 1/0.5; 1/1, and 0/2. Time-kill studies were performed with the 0-, 0.5-, 2-, 4-, 6-and 8-h sera after dose against a clinical isolate of A. baumannii (sulbactam MIC, 4µg/mL). Bactericidal activity (i.e. a mean decrease ≥3 log 10 CFU/mL in the viable cell counts from the initial inoculum) was displayed by the 0.5-and the 2-h sera after dose for all formulations. The 4-h sera proved inhibitory with the AMX-SUL 1g/1g formulation, albeit a trend to regrowth was observed after 24-h incubation. With the AMX-SUL 0g/2g dose, the 4-h sera proved almost bactericidal activity (i.e. a mean decrease of 2.4 log 10 CFU/mL in the viable cell counts from the initial inoculum), whereas the 6-h sera was inhibitory, with a trend to regrowth after 24-h incubation. When infused over 3h, AMX-SUL 1g/0.5g and 1g/1g, bactericidal activity was displayed by the 0.5-, 2-and the 4-h sera after dose and the 6-h sera proved inhibitory with the AMX-SUL 1g/1g formulation. The present study, albeit preliminary, might give a rationale for the dosing strategy to treat infections caused by A. baumannii with sulbactam, either alone or combined with amoxicillin. A 2-g sulbactam dose seems to be optimal to be infused over 30 min with a 6-h dosing interval. When infused over 3h, AMX-SUL 1g/1g given every 6h or 8h seems a suitable dosing schedule.

show abstract

Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program

Cited by 61 publications

References 24 publications

The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting

The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting

Factores de riesgo para la adquisición y características microbiológicas de las bacteriemias por Acinetobacter baumannii multi-resistente en pediatría: Estudio de casos y controles

Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model

Contact Info

Product

Resources

About